Search

Your search keyword '"Scripture, Charity D."' showing total 20 results
Start Over Author "Scripture, Charity D."
20 results on '"Scripture, Charity D."'

1. PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial

Author

Stein, Mark N., Dumbrava, Ecaterina E., Teply, Benjamin A., Gergis, Usama S., Guiterrez, Martin E., Reshef, Ran, Subudhi, Sumit K., Jacquemont, Céline F., Senesac, Joseph H., Bayle, J. Henri, Scripture, Charity D., Chatwal, Monica S., Bilen, Mehmet A., Stadler, Walter M., and Becerra, Carlos R.

Published
2024
Full Text
View/download PDF

8. Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.

Author

Malhotra, Jyoti, primary, Nikolinakos, Petros, additional, Leal, Ticiana, additional, Lehman, Jonathan, additional, Morgensztern, Daniel, additional, Patel, Jyoti D., additional, Wrangle, John M., additional, Curigliano, Giuseppe, additional, Dansin, Eric, additional, Greillier, Laurent, additional, Johnson, Melissa Lynne, additional, Ready, Neal, additional, Robinet, Gilles, additional, Lally, Satwant, additional, Wong, Shekman, additional, Avsar, Emin, additional, Valenzuela, Ricardo, additional, Scripture, Charity D., additional, Selvaggi, Giovanni, additional, and Besse, Benjamin, additional

Published
2019
Full Text
View/download PDF

9. Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).

Author

Akamatsu, Hiroaki, primary, Udagawa, Hibiki, additional, Tanaka, Kentaro, additional, Takeda, Masayuki, additional, Kanda, Shintaro, additional, Kirita, Keisuke, additional, Teraoka, Shunsuke, additional, Nakagawa, Kazuhiko, additional, Fujiwara, Yutaka, additional, Yasuda, Ikuko, additional, Okubo, Sumiko, additional, Shintani, Masayuki, additional, Leibman, Rachel S, additional, Scripture, Charity D., additional, Tamura, Tomohide, additional, and Okamoto, Isamu, additional

Published
2019
Full Text
View/download PDF

15. Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

Author

Sparreboom, Alex, primary, Scripture, Charity D., additional, Trieu, Vuong, additional, Williams, Paul J., additional, De, Tapas, additional, Yang, Andrew, additional, Beals, Bridget, additional, Figg, William D., additional, Hawkins, Michael, additional, and Desai, Neil, additional

Published
2005
Full Text
View/download PDF

18. Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications

Author

Lepper, Erin R., Smith, Nicola F., Cox, Michael C., Scripture, Charity D., and Figg, William D.

Abstract

Despite its controversial past, thalidomide is currently under investigation for the treatment of several disease types, ranging from inflammatory conditions to cancer. The mechanism of action of thalidomide is complex and not yet fully understood, but there is some evidence to suggest that metabolism may play a role. Consequently, there has been a considerable effort to characterize the metabolism of thalidomide in recent years. Thalidomide undergoes biotransformation by non-enzymatic hydrolysis and enzyme-mediated hydroxylation to form a multitude of metabolites. Metabolite identification and reaction phenotyping studies have been performed and will be discussed in this review in addition to interspecies differences in thalidomide metabolism.

Published
2006

19. Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives

Author

Scripture, Charity D., Figg, William D., and Sparreboom, Alex

Abstract

Paclitaxel is an antineoplastic agent derived from the bark of the western yew, Taxus brevifolia, with a broad spectrum of activity. Because paclitaxel promotes microtubule assembly, neurotoxicity is one of its side effects. Clinical use of paclitaxel has led to peripheral neuropathy and this has been demonstrated to be dependent upon the dose administered, the duration of the infusion, and the schedule of administration. Vehicles in the drug formulation, for example Cremophor in Taxol®, have been investigated for their potential to induce peripheral neuropathy. A variety of neuroprotective agents have been tested in animal and clinical studies to prevent paclitaxel neurotoxicity. Recently, novel paclitaxel formulations have been developed to minimize toxicities. This review focuses on recent advances in the etiology of paclitaxel-mediated peripheral neurotoxicity, and discusses current and ongoing strategies for amelioration of this side effect.

Published
2006

20. Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).

Author

Scripture CD, Szebeni J, Loos WJ, Figg WD, and Sparreboom A

Subjects
Adult, Aged, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Agents, Phytogenic blood, Chemistry, Pharmaceutical, Dose-Response Relationship, Drug, Excipients administration & dosage, Excipients pharmacology, Female, Glycerol analogs & derivatives, Humans, In Vitro Techniques, Male, Mathematics, Micelles, Middle Aged, Paclitaxel administration & dosage, Paclitaxel blood, Solvents administration & dosage, Solvents pharmacology, Surface Tension, Water chemistry, Antineoplastic Agents, Phytogenic pharmacokinetics, Paclitaxel pharmacokinetics, Surface-Active Agents pharmacokinetics
Abstract

Purpose: Taxol contains paclitaxel formulated in Cremophor EL-P (CrEL-P) and ethanol. Paxene is similar to Taxol, except for the use of Cremophor EL (CrEL) and the addition of citric acid. Here, we investigated the physicochemical properties and clinical pharmacokinetics of the two paclitaxel formulations., Experimental Design: The size and modality of distribution of CrEL-P and CrEL micelles was determined by dynamic-light scattering. The effect of vehicle composition on the fraction unbound paclitaxel in vitro was determined by equilibrium dialysis. Paclitaxel pharmacokinetics were studied in 61 cancer patients receiving Taxol and 26 patients receiving Paxene. Comparative pharmacokinetics of CrEL-P and CrEL were obtained in 14 and 6 patients, respectively., Results: The size of micelles present in Taxol was slightly smaller (9 to 13%) than those present in Paxene. Surface tension and critical micellar concentration were also similar for the two formulations, with mean values of 37.0 and 38.1 mN/m and 0.0387 and 0.0307 mg/mL, respectively. The fraction unbound paclitaxel was not significantly different for Taxol and Paxene (p > 0.05). Over the tested dose range, the mean clearance of paclitaxel decreased from 45.1 to 16.9 L/h for Taxol, and from 50.7 to 16.4 L/h for Paxene (p > 0.05). Concentrations of the excipient following the administration of CrEL-P or CrEL were also similar., Conclusion: The differences in formulation between Taxol and Paxene do not significantly affect micelle formation and/or quantitative aspects of the vehicle-paclitaxel interaction in vitro and in vivo.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results